Drug Development Pharma - March 10, 2015
CHMP Clears Drug Label Update
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a label update of H. Lundbeck A/S’s Brintellix® for its effect on certain aspects of cognitive function in patients with depression. This will be the first summary of the product characteristics of an antidepressant to […]
Drug Development Pharma - October 9, 2013
Takeda and Lundbeck announce FDA approval of Brintellix
Takeda Pharmaceutical Company and H. Lundbeck A/S jointly have announced that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD). “MDD is a multifaceted disorder that encompasses emotional, physical and cognitive symptoms that may make it challenging to treat,” said Michael Thase, M.D., […]
